PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA

Bibliographic Details
Main Authors:	Shengjie Wang, Lan Zhang, Keyi Jin, Shiwei Hu, Xinlu Zhang, Danhong Xiang, Qiutian Feng, Lingrong Tu, Jie Jin, Jian Huang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975592.83600.cf

Similar Items

Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
by: P. Akyol, et al.
Published: (2020-10-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Monika Conchon
Published: (2011-12-01)

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY
by: Danhong Xiang, et al.
Published: (2023-08-01)

CLINICAL, CYTOGENETIC AND MOLECULAR CHARACTERIZATION OF BRAZILIAN COHORT PATIENTS WITH PRIMERY MYELOFIBROSIS AND MYELOFIBROSIS POST-POLYCYTTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA
by: RS Tavares, et al.
Published: (2021-10-01)

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
by: B. Mora, et al.
Published: (2022-06-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis
by: Laura Pelagatti, et al.
Published: (2024-04-01)

Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review
by: Li Li, et al.
Published: (2023-09-01)

Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis
by: Sebastian Francis, et al.
Published: (2024-04-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective studyResearch in context
by: Danhong Xiang, et al.
Published: (2024-01-01)

Acute phase reactants in chronic inflammation leading to secondary myelofibrosis in polycythemia vera and essential thrombocytosis
by: E. Aladag, et al.
Published: (2020-10-01)

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera
by: Sylvain Lescuyer, et al.
Published: (2019-03-01)

Updates in the management of polycythemia vera and essential thrombocythemia
by: Prithviraj Bose, et al.
Published: (2019-08-01)

Targeted Sequencing of Sorted Peripheral Blood Cells Reveals Novel Germline and Somatic Variants in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
by: Wong, C.L., et al.
Published: (2015)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
by: Alessandra Carobbio, et al.
Published: (2023-07-01)

Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
by: Hidenari Hasui, et al.
Published: (2022-06-01)

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01)

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
by: Andreas Hanssønn Habberstad, et al.
Published: (2018-04-01)

DEREGULATION OF BONE MARROW EICOSANOIDS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS PATIENTS
by: J.G. Cominal, et al.
Published: (2020-11-01)

Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
by: M A Sokolova, et al.
Published: (2016-12-01)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
by: Barnali Srivastava, et al.
Published: (2023-09-01)

<i>TET2</i> rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
by: Diana L. Lighezan, et al.
Published: (2020-12-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
by: J. Huang, et al.
Published: (2022-06-01)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
by: Taghi Manshouri, et al.
Published: (2022-05-01)

Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
by: Julien M. P. Grenier, et al.
Published: (2024-01-01)

DNA Methylation Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
by: Wong, C.L., et al.
Published: (2015)

Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
by: William Vainchenker, et al.
Published: (2016-04-01)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
by: Daniele Cattaneo, et al.
Published: (2022-04-01)

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
by: Kittitat Chiaranairungrot, et al.
Published: (2022-12-01)

Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia
by: Danijela Lekovic, et al.
Published: (2023-08-01)

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
by: E Morsia, et al.
Published: (2021-01-01)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
by: Patryk Sobieralski, et al.
Published: (2023-08-01)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
by: Monica Sacco, et al.
Published: (2020-03-01)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
by: Vincenzo Accurso, et al.
Published: (2019-12-01)